Medical Weight Loss in the East Valley: A Guide to GLP-1 Options
Not all GLP-1 weight loss programs are the same — and not all are FDA-approved.
Is compounded semaglutide safe, and is it right for you?
Here is the direct answer: compounded semaglutide can be prescribed by a licensed practitioner, but it is not FDA-approved and is not the same as Wegovy or Zepbound. Whether it is appropriate for you depends on your health history, labs, and goals.
At IWCAZ, medical weight loss in the East Valley starts with a structured first appointment where a naturopathic doctor reviews what is driving your weight concerns and whether a supervised GLP-1 program makes sense for you. This post explains what that program involves, who may be a candidate, and what to expect at your first visit.
What Compounded Semaglutide Is — and What It Isn't
Semaglutide and tirzepatide are GLP-1 receptor agonists. They reduce appetite and slow digestion, originally developed to manage blood sugar in type 2 diabetes.
Compounded versions are not FDA-approved. They are prepared by licensed compounding pharmacies under a practitioner's prescription, and are not considered therapeutically equivalent to brand-name products. Any reputable provider will tell you that upfront.
The FDA updated its guidance on compounded GLP-1 medications in early 2026. Licensed practitioners and pharmacies operating within applicable rules can still prescribe and dispense them, but the regulatory landscape is evolving — which is exactly why supervision is not optional. It is the point.
Learn more about our Medical Weight Loss program
Who May Be a Candidate for Medical Weight Loss in the East Valley
A supervised GLP-1 program may be appropriate for adults who:
- Have a BMI of 27 or higher with at least one weight-related health concern, or a BMI of 30 or higher
- Are not currently pregnant or breastfeeding
- Do not have a personal or family history of medullary thyroid carcinoma or MEN2 syndrome
- Are looking for clinical support beyond lifestyle changes alone
- Are willing to participate in regular monitoring and follow-up
A consultation is not a commitment, and it is not a guarantee of a prescription. Your ND reviews your full picture first.
What Your First Appointment Actually Looks Like
At a first visit, your ND will review your BMI, recent labs, current medications, and weight history. If you have prior bloodwork — thyroid function, fasting glucose, lipids — bring it.
If a supervised program looks appropriate, dosing begins low. The first four weeks are a titration phase: the goal is finding a dose that reduces appetite without significant nausea or fatigue. Meaningful weight changes come later, typically in months two through six, and vary by individual.
Follow-up appointments are scheduled regularly to adjust dosing and assess progress.
Supervised vs. Telehealth-Only: Why the Difference Matters
The gap between a supervised East Valley medical weight loss program and a telehealth-only script is not administrative — it is clinical.
At IWCAZ, your ND looks at root causes that can interfere with weight loss: hormonal function, thyroid status, sleep, stress physiology, gut health. Identifying these before prescribing changes the program design. When appropriate, we may also recommend complementary care such as a hormone therapy evaluation or IV therapy.
That integration is what distinguishes IWCAZ from a subscription service with no clinical follow-through.
Key Takeaways
- GLP-1 medications require clinical supervision. Compounded semaglutide and tirzepatide are prescription medications dispensed under a licensed practitioner's order.
- Compounded does not equal FDA-approved. These are not therapeutically equivalent to brand-name drugs. Any reputable provider says so clearly.
- IWCAZ is practitioner-supervised, not telehealth-only. Your ND reviews full health history, labs, and root causes before recommending anything.
- Who is a candidate: Adults with BMI 27+ plus a weight-related health concern, or BMI 30+, not pregnant, no GLP-1 contraindications.
- What to expect at first consult: Lab review, health history, goal-setting, and a candid conversation about whether a supervised GLP-1 program fits you.
References
- U.S. Food and Drug Administration. GLP-1 Receptor Agonist Compounding Guidance (2025-2026). fda.gov
- Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. DOI: 10.1056/NEJMoa2032183
- Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216. DOI: 10.1056/NEJMoa2206038
- American Association of Naturopathic Physicians (AANP). Scope of Naturopathic Practice. naturopathic.org
Book a Medical Weight Loss Consultation in the East Valley
Ready to understand your options from a practitioner who reviews the full clinical picture?
Book a 30-minute new-patient consultation with one of our NDs — most consults are scheduled within a week.
Schedule online | Call (480) 906-4735
IWCAZ serves patients across Mesa, Gilbert, Chandler, and Scottsdale.
Medical Disclaimer: This blog post is for general informational and educational purposes only and does not constitute medical advice. GLP-1 medications are prescription therapies. Candidacy, dosing, and treatment decisions should always be made in consultation with a qualified healthcare provider who has reviewed your complete medical history. Compounded medications are not FDA-approved drug products. Results vary by individual.
